24480-38-4 Usage
Description
(1S)-3,5,5-trimethyl-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyl-18-(2,6,6-trimethyl-1-cyclohexenyl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohex-3-en-1-ol is a complex organic compound with a long chain of carbon atoms and multiple double bonds, featuring various methyl and cyclohexenyl groups. Its structure suggests it may have potential applications in various industries due to its unique chemical properties.
Uses
Used in Pharmaceutical Industry:
(1S)-3,5,5-trimethyl-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyl-18-(2,6,6-trimethyl-1-cyclohexenyl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohex-3-en-1-ol is used as a potential therapeutic agent for various medical conditions due to its unique chemical structure and the presence of multiple functional groups that can interact with biological targets.
Used in Cosmetics Industry:
In the cosmetics industry, (1S)-3,5,5-trimethyl-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyl-18-(2,6,6-trimethyl-1-cyclohexenyl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohex-3-en-1-ol may be used as an ingredient in skincare products, leveraging its chemical properties to provide benefits such as moisturization, anti-aging, or protection against environmental stressors.
Used in Food Industry:
As an antioxidant, (1S)-3,5,5-trimethyl-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyl-18-(2,6,6-trimethyl-1-cyclohexenyl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohex-3-en-1-ol could be utilized in the food industry to extend the shelf life of products, protect them from oxidation, and maintain their nutritional value.
Used in Agricultural Industry:
In agriculture, (1S)-3,5,5-trimethyl-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyl-18-(2,6,6-trimethyl-1-cyclohexenyl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohex-3-en-1-ol might be employed as a component in the development of biopesticides or as an additive to enhance the nutritional content of animal feed.
Please note that the above uses are speculative based on the compound's structure and the general applications of similar compounds. Further research and development would be required to confirm these potential uses and to establish safety and efficacy profiles.
Purification Methods
It crystallises from *C6H6/MeOH in red needles. The racemate is purified through an Al2O3 column, eluting with *C6H6 and recrystallising from MeOH/Et2O. It has λmax (ε 10-3) (hexane) at 421, 444, 471nm (90, 133, 122). [Loeber et al. J Chem Soc (C) 404 1971, Goodfellow et al. J Chem Soc, Chem Commun 1578 1970, Beilstein 6 IV 5113.]
Check Digit Verification of cas no
The CAS Registry Mumber 24480-38-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,4,4,8 and 0 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 24480-38:
(7*2)+(6*4)+(5*4)+(4*8)+(3*0)+(2*3)+(1*8)=104
104 % 10 = 4
So 24480-38-4 is a valid CAS Registry Number.
24480-38-4Relevant articles and documents
Synthesis of (3 R,3 R)-zeaxanthin and its meso -stereoisomer from (3 R,3 R,6 R)-lutein via (3 R)-3,4-anhydrolutein
Khachik, Frederick
, p. 453 - 459 (2012/03/27)
A process has been developed for the partial synthesis of (3R,3R)-zeaxanthin and (3R,3S; meso)-zeaxanthin from commercially available (3R,3R,6R)-lutein. This involves the regioselective hydroboration of a dehydration product of lutein, namely (3R)-3,4-didehydro-,-caroten-3-ol [(3R)-3,4-anhydrolutein], to yield a mixture of (3R,3R)-zeaxanthin and (3R,3S; meso)-zeaxanthin followed by separation of these carotenoids by enzyme-mediated acylation. (3R,3R,6R)-Lutein, (3R,3R)-zeaxanthin and its meso-isomer accumulate in human ocular tissues and have been implicated in the prevention of age-related macular degeneration (AMD). Georg Thieme Verlag Stuttgart New York.
Process for Synthesis of (3R,3'R)-Zeaxanthin and (3R,3'S;meso)-Zeaxanthin from (3R,3'R,6'R)-Lutein via (3R)-3',4'-Anhydrolutein
-
Page/Page column 7; 9, (2009/10/01)
(3R, 3′R, 6′R)-Lutein and (3R, 3′R)-zeaxanthin are two dietary carotenoids that are present in most fruits and vegetables commonly consumed in the US and accumulate in the human plasma, major organs, and ocular tissues. Another stereoisomer of (3R, 3′R)-zeaxanthin that is not of dietary origin but is found in the human ocular tissues is (3R, 3′S; meso)-zeaxanthin. There is growing evidence that these carotenoids play an important role in the prevention of age-related macular degeneration (AMD) that is the leading cause of blindness in the U.S. and the Western World. In view of the potential therapeutic application of dietary lutein, (3R, 3′R)-zeaxanthin, and (3R, 3′S; meso)-zeaxanthin, the industrial production of these carotenoids is of considerable importance. The present invention provides a process for the partial synthesis of (3R, 3′R)-zeaxanthin and (3R, 3′S; meso)-zeaxanthin from a readily accessible dehydration product of (3R, 3′R, 6′R)-lutein, namely, (3R)-3′,4′-didehydro-β,β-caroten-3-ol [(3R)-3′,4′-anhydrolutein]. The process involves regioselective hydroboration of (3R)-3′,4′-anhydrolutein to a mixture of (3R, 3′R)-zeaxanthin and (3R, 3′S; meso)-zeaxanthin followed by separation of these carotenoids by enzyme-mediated acylation.
Method for production of rare carotenoids from commercially available lutein
-
Page/Page column 11-12, (2008/06/13)
Disclosed are processes for conversion of (3R,3′R,6′R)-lutein to (3R,6′R)-α-cryptoxanthin, (3R)-β-cryptoxanthin, anhydroluteins I, II, and III (dehydration products of lutein), and a method for separating and purifying the individual carotenoids including the unreacted (3R,3′R)-zeaxanthin. The invention also includes two methods that transform (3R,3′R,6′R)-lutein into (3R,6′R)-α-cryptoxanthin in excellent yields.
